TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE FINNISH GENERAL POPULATION

被引:56
|
作者
Hamalainen, Juha [1 ,2 ]
Isometsa, Erkki [1 ,3 ]
Sihvo, Sinikka [4 ]
Kiviruusu, Olli [1 ]
Pirkola, Sami [3 ]
Lonnqvist, Jouko [1 ]
机构
[1] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, SF-00300 Helsinki, Finland
[2] Eastern Hlth Ctr, Helsinki City Hlth Dept, Dept Psychiat, Helsinki, Finland
[3] Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland
[4] Natl Res & Dev Ctr Welf & Hlth, STAKES, Helsinki, Finland
关键词
treatment; major depressive disorder; general population; MENTAL-DISORDERS; BENZODIAZEPINE USE; UNITED-STATES; PRIMARY-CARE; PSYCHOTROPIC MEDICATION; OUTPATIENT TREATMENT; TREATMENT ADEQUACY; ANXIETY DISORDERS; HEALTH-SERVICES; NATIONAL TRENDS;
D O I
10.1002/da.20524
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Few general population studies of the treatment of major depressive disorder (MDD) have included the whole spectrum of treatments. We estimated the rates of different treatments and the effect of individual and disorder characteristics plus provider type on treatment received. Methods: In the Health 2000 Study, a representative sample (n = 6,005) from the adult Finnish population (>= 30 years) were interviewed (CIDI) in 2000-2001 for the presence of DSM-IV mental disorders during the past 12 months. Logistic regression models were used to examine factors influencing the type of treatment. either pharmacotherapies (antidepressants, anxiolytics, sedatives/hypnotics, antipsychotics) or psychological treatment. Results: Of the individuals with MDD (n = 288), currently 24% used antidepressants, 11% anxiolytics, 16% sedatives/hypnotics, 5% antipsychotics, and 17% reported having received psychological treatment. Overall, 31% received antidepressants or psychological treatment or both; 18% received minimally adequate treatment. Of those 33% (n = 94) using health care services for mental reasons, 76% received antidepressants or psychological treatment or both; 54% received minimal adequate treatment. In logistic regression models, the use of antidepressants was associated with female sex, being single, severe MDD, perceived disability, and comorbid dysthymic disorder; psychological treatment with being divorced, perceived disability, and comorbid anxiety disorder Conclusions: Due to the low use of health services for mental reasons, only one-third of subjects with MDD use antidepressants, and less than one-fifth receives psychological treatment. The treatments provided are determined mostly by clinical factors such as severity and comorbidity, in part by sex and marital status, but not education or income. Depression and Anxiety 26.1049-1059, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:1049 / 1059
页数:11
相关论文
共 50 条
  • [21] Desvenlafaxine in the treatment of major depressive disorder
    Pae, Chi-Un
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) : 2923 - 2928
  • [22] Major Depressive Disorder in the African American Population
    Drakes, Wilma A.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2012, 104 (9-10) : 463 - 464
  • [23] Major Depressive Disorder in the African American Population
    Bailey, Rahn K.
    Patel, Milapkumar
    Barker, Narviar C.
    Ali, Shahid
    Jabeen, Shagufta
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2011, 103 (07) : 548 - 557
  • [24] DEPRESSIVE PERSONALITY AND TREATMENT OUTCOME IN MAJOR DEPRESSIVE DISORDER
    Ryder, Andrew G.
    Quilty, Lena C.
    Vachon, David D.
    Bagby, R. Michael
    JOURNAL OF PERSONALITY DISORDERS, 2010, 24 (03) : 392 - 404
  • [25] Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population
    Wu, Eric
    Greenberg, Paul E.
    Yang, Elaine
    Yu, Andrew
    Erder, M. Haim
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (09) : 2587 - 2595
  • [26] Psychotropic medication in Spanish population setting: treatment adequacy for major depressive disorder
    Blanca-Tamayo, M.
    Sicras-Mainar, A.
    Pascual-Arce, B.
    Perez-Navarro, M. C.
    Navarro-Artieda, R.
    Garcia-Sanchez, L.
    Muro-Perea, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S422 - S423
  • [27] Relationship between major depressive disorder, generalized anxiety disorder and coronary artery disease in the US general population
    Liu, Hongwei
    Tian, Ye
    Liu, Yan
    Nigatu, Yeshambel T.
    Wang, Jianli
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2019, 119 : 8 - 13
  • [28] Objective polysomnography-based sleep features and major depressive disorder subtypes in the general population
    Solelhac, Geoffroy
    Berger, Mathieu
    Strippoli, Marie-Pierre F.
    Marchi, Nicola Andrea
    Stephan, Aurelie
    Petit, Jean-Marie
    Bayon, Virginie
    Imler, Theo
    Haba-Rubio, Jose
    Raffray, Tifenn
    Vollenweider, Peter
    Marques-Vidal, Pedro
    Waeber, Gerard
    Legar, Damien
    Siclari, Francesca
    Geoffroy, Pierre A.
    Preisig, Martin
    Heinzer, Raphael
    PSYCHIATRY RESEARCH, 2023, 324
  • [29] A Sex-Specific Comparison of Major Depressive Disorder Symptomatology in the Canadian Forces and the General Population
    Erickson, Julie
    Kinley, D. Jolene
    Bolton, James M.
    Zamorski, Mark A.
    Enns, Murray W.
    Sareen, Jitender
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2014, 59 (07): : 393 - 398
  • [30] The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies
    Gill, Hartej
    Puramat, Parnian
    Patel, Pankti
    Gill, Barjot
    Marks, CeAnn A.
    Rodrigues, Nelson B.
    Castle, David
    Cha, Danielle S.
    Mansur, Rodrigo B.
    Rosenblat, Joshua Daniel
    McIntyre, Roger S.
    PSYCHIATRY RESEARCH, 2022, 313